Entrada Therapeutics, Inc.
TRDADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How TRDA's past catalysts played out
ENTR-601-44
Duchenne Muscular Dystrophy (DMD)
ENTR-601-45
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ENTR-601-44 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
ENTR-601-45 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Frequently asked questions
What is in Entrada Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Entrada Therapeutics, Inc.'s (TRDA) pipeline across Phase 2. Its lead program is ENTR-601-44 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entrada Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Entrada Therapeutics, Inc. (TRDA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TRDA biotech catalysts?→
Add TRDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entrada Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.